Connecticut is currently home to 1213 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
NCT06205706
Recruiting
The goal of this first in human clinical trial is to test BI-1910 administered as single agent and in combination with pembrolizumab in subjects with advanced/metastatic solid tumors whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1910 * what is maximum tolerated or administrated dose * to determine recommended dose for further clinical trials Participants will receive infusions of BI-1910 alone or combination with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2024
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma
Register for Updates
Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)
NCT04599478
Recruiting
This study will compare the effectiveness of behavioral and pharmacologic treatments, alone and in combination, for the treatment of loss-of-control eating and weight following bariatric surgery. This is an acute treatment comparing behavioral weight loss alone or in combination with combination naltrexone/bupropion medication.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/22/2024
Locations: Yale Department of Psychiatry, New Haven, Connecticut
Conditions: Loss-of-control Eating, Obesity/Overweight
Register for Updates
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
NCT03128996
Recruiting
This study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benefit from the procedure.
Gender:
ALL
Ages:
Between 1 day and 21 years
Trial Updated:
07/22/2024
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders, Immunologic Disorders, Hemoglobinopathies, Non-malignant Disorders
Register for Updates
Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
NCT06411210
Recruiting
More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. GLP-1 analogues are anti-obesity medications that are cardioprotective in adults with type 2 diabetes, however evaluation of these agents in people with T1D has been limited to glycemic outcomes. Investigators aim to study the impact of GLP-1 analogue obesity treatment on markers of cardiometabolic risk in young adults with T1D and... Read More
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
07/19/2024
Locations: Yale Pediatric Diabetes Center, Adult and Children's Progam, New Haven, Connecticut
Conditions: Diabetes type1, Obesity
Register for Updates
Blood Pressure Variability and Ischemic Stroke Outcome
NCT05756257
Recruiting
The goal of this observational study is to evaluate the role of blood pressure (BPV) variability in patients suffering from acute ischemic stroke. The main questions it aims to answer are: 1. To determine the association of BPV with functional/cognitive outcome after ischemic stroke. 2. To determine a pathophysiologic mechanism of BPV's deleterious effect on functional outcome. 3. To evaluate potential treatment targets to pharmacologically reduce BPV after ischemic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2024
Locations: Yale-New Haven Hospital, New Haven, Connecticut
Conditions: Acute Ischemic Stroke, Blood Pressure Variability
Register for Updates
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
NCT00920972
Recruiting
The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
07/19/2024
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
Register for Updates
Stress and Congestive Heart Failure
NCT04551560
Recruiting
The purpose of this study is to investigate whether acute stress can precipitate congestive heart failure (CHF) exacerbation in patients with CHF.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: St. Francis Hospital, Hartford, Connecticut
Conditions: Congestive Heart Failure
Register for Updates
A Trial to Determine Weight Gain Benefits of Caloric Supplementation for NAS Infants
NCT04419857
Recruiting
A randomized clinical study in NAS infants managed via the Eat, Sleep, Console (ESC) approach comparing early weight loss on a standard-caloric density versus high-caloric density feeding regimen.
Gender:
ALL
Ages:
All
Trial Updated:
07/16/2024
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Neonatal Abstinence Syndrome
Register for Updates
The Impact of Blood Flow Restriction Training in Adolescents After ACL Reconstruction: A Randomized Controlled Trial
NCT05754632
Recruiting
While there are a number studies that have reported on the use of blood flow restriction training (BFRT) in the adult population, there is limited information about the use of BFRT in the adolescent population. This study aims to evaluate the use of BFRT in conjunction with traditional anterior ligament reconstruction (ACLR) rehabilitation in adolescents. The purpose of this study is to compare the addition of a BFRT based exercise protocol to a standard ACL rehabilitation protocol in adolescen... Read More
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
07/15/2024
Locations: Connecticut Children's Sports Physical Therapy, Farmington, Connecticut
Conditions: Anterior Cruciate Ligament Injuries, Knee Injuries, Quadriceps Muscle Atrophy
Register for Updates
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
NCT05785819
Recruiting
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT). Participants with suspected HIT will receive the usual standard of care, and will be assigned randomly to either VLX-1005 or placebo treatment. The study will measure important outcomes including platelet count, stroke, pulmonary embolus (clot to the lungs) and bleeding.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia
Register for Updates
Chronotherapy in Children With Chronic Kidney Disease
NCT05353335
Recruiting
This is a pilot, crossover trial in which the investigator will determine if retiming of one anti-hypertensive medication from morning to evening can effectuate normal blood pressure dipping patterns in children and adolescents with chronic kidney disease.
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
07/12/2024
Locations: Yale New Haven Children's Hospital/Yale New Haven Health, New Haven, Connecticut
Conditions: Chronic Kidney Diseases, Hypertension
Register for Updates
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
NCT03997370
Recruiting
This trial studies how well iohexol works in helping doctors calculate the dose of carboplatin given to patients with cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/11/2024
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Malignant Solid Neoplasm
Register for Updates